Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545957 · ClinicalTrials.gov registry record · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
A NA study of Prostate Cancer and Head and Neck Cancer, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 86
- Enrollment target
- 2
- Study locations
NCT04545957: Recruiting NA study of Prostate Cancer and Head and Neck Cancer, sponsored by Brigham and Women's Hospital.
NCT04545957 is a NA study of Prostate Cancer and Head and Neck Cancer that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 86 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04545957, a NA study of Prostate Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
Primary Outcome
Feasibility is defined as successfully enrolling patients, successfully acquiring MR data at the specified timepoint in a patient's care plan and ability to identify the radiation target and develop a radiation therapy plan on the MR data
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DEVICE MRI Simulator
Study Locations (2)
Massachusetts
- Brigham and Women Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2030-10-22 |
| Phase | NA |
What NCT04545957 shows while recruiting
NCT04545957 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT04545957 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04545957 about?
NCT04545957 is a clinical study titled "Jump: MR Simulation For Radiation Therapy Master Protocol". This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
What is the current status of trial NCT04545957?
This trial is currently recruiting. It is a NA study. The enrollment target is 86 participants. The study started on 2020-10-14. Estimated completion is 2030-10-22.
What conditions does trial NCT04545957 study?
This clinical trial studies the following conditions: Prostate Cancer, Head and Neck Cancer, Liver Cancer, Recurrent Adenocarcinoma.
What interventions are being tested in trial NCT04545957?
The interventions under investigation include: Radiation Therapy (RADIATION), MRI Simulator (DEVICE).
Who is sponsoring clinical trial NCT04545957?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04545957 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04545957's enrollment target sits among peer trials
86 363rd of 735 higher than 373 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04633252 · 86 participants · Phase 1
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI